People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.

Depression impacts an estimated 18 million Americans each year, yet depression screening rarely occurs in the outpatient setting.

CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...

The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...

Scientists at Virginia Tech are revolutionizing depression treatment by tapping into how the brain processes rewards. Their ...

Depression is prevalent in children, requiring early diagnosis and treatment. Learn about child depression symptoms, causes ...

The announcement was welcome news for those with major depressive disorder, which affects an estimated 8.3% of the adult ...

The FDA’s decision marks J&J's Spravato as the first monotherapy for adults with treatment-resistant depression.

The nasal spray Spravato, which is made from the drug esketamine, had been approved in 2019 for patients who failed to ...

The FDA has approved Spravato (esketamine) nasal spray for use as monotherapy for patients with treatment-resistant depression.

The U.S. Food and Drug Administration expanded approval for Johnson & Johnson’s nasal spray, Spravato, to allow it to be used ...

The Food and Drug Administration on Tuesday approved Johnson & Johnson's nasal spray to be used alone in adults with a major ...